Gilead today released its Year in Review 2019, the annual report highlighting the company’s efforts to develop transformative medicines, support employees, partner with communities around the world and grow the business sustainably.
“When I joined Gilead in early 2019, I saw tremendous potential to build on the company’s legacy – a legacy that includes two of the most extraordinary advances in healthcare of the past decade: transforming HIV into a chronic disease and curing hepatitis C,” Chairman and Chief Executive Officer Daniel O’Day writes in a letter included in the report. “As I reflect on the progress that we made together over the course of the year, I am pleased with how far we have come and tremendously optimistic about our future. We are more than ready for the many opportunities ahead to improve global health.”
The report features stories about many of the company’s efforts to create new possibilities for people living with serious diseases around the world, including:
An overview of the company’s efforts to deliver 10+ transformative therapies in the next 10 years
- Features on the Rainbow Grant program, Gilead COMPASS Initiative and other initiatives highlighting the company’s work with partners around the world to help reduce health disparities
- A story on the use of green chemistry practices and other measures that are helping Gilead meet its sustainability goals and build a resilient business
- Updates on Kite’s progress advancing innovative cell therapies for people with cancer